The range in sample size with lower number of samples for chenodeoxycholic acid and deoxycholic acid was attributed to the interfering of the BA with CFTR-potentiators e.g., Ivacaftor, given to patients with Cystic Fibrosis [17]. Here, CFTR is linked to cystic fibrosis.